The Severity of Chronic Cough Diary (SCCD): development and content validation of a novel patient-reported outcome instrument for evaluating the symptom experience of chronic cough

[1] Morice AH(2020)ERS guidelines on the diagnosis and treatment of chronic cough in adults and children Eur Respir J 55 1901136-1481

[2] Millqvist E(2015)The global epidemiology of chronic cough in adults: a systematic review and meta-analysis Eur Respir J 45 1479-66

[3] Bieksiene K(2021)Chronic cough: new insights and future prospects Eur Respir Rev 30 210127-1205

[4] Birring SS(2023)Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic cough Ann Allergy Asthma Immunol 130 60-02020

[5] Dicpinigaitis P(2015)P2 × 3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study Lancet 385 1198-785

[6] Domingo Ribas C(2020)Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2 × 3 receptor antagonist, in refractory or unexplained chronic cough ERJ Open Res 6 00284-1358

[7] Song WJ(2020)Gefapixant, a P2 × 3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial Lancet Respir Med 8 775-343

[8] Chang YS(2020)Pharmacotherapeutic options for chronic refractory cough Expert Opin Pharmacother 21 1345-1131

[9] Faruqi S(2003)Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ) Thorax 58 339-1110

[10] Kim JY(2002)Evaluation of a cough-specific quality-of-life questionnaire Chest 121 1123-1589

[1] Morice AH(2020)ERS guidelines on the diagnosis and treatment of chronic cough in adults and children Eur Respir J 55 1901136-1481

[2] Millqvist E(2015)The global epidemiology of chronic cough in adults: a systematic review and meta-analysis Eur Respir J 45 1479-66

[3] Bieksiene K(2021)Chronic cough: new insights and future prospects Eur Respir Rev 30 210127-1205

[4] Birring SS(2023)Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic cough Ann Allergy Asthma Immunol 130 60-02020

[5] Dicpinigaitis P(2015)P2 × 3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study Lancet 385 1198-785

[6] Domingo Ribas C(2020)Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2 × 3 receptor antagonist, in refractory or unexplained chronic cough ERJ Open Res 6 00284-1358

[7] Song WJ(2020)Gefapixant, a P2 × 3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial Lancet Respir Med 8 775-343

[8] Chang YS(2020)Pharmacotherapeutic options for chronic refractory cough Expert Opin Pharmacother 21 1345-1131

[9] Faruqi S(2003)Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ) Thorax 58 339-1110

[10] Kim JY(2002)Evaluation of a cough-specific quality-of-life questionnaire Chest 121 1123-1589